India Boosts Pharma-MedTech Innovation with PRIP Workshop

13 Mar 2025 CW Team

The workshop focused on strengthening India’s innovation ecosystem in pharmaceuticals and medical technology. Shri Amit Agrawal highlighted the sector's rapid growth, noting the rising global share of advanced technologies like antibody-drug conjugates and gene therapy — projected to reach 20% of the top-100 drugs by value by 2030. He also pointed to the remarkable tenfold increase in Indian healthcare and life sciences startups, from 900 in 2020 to over 10,000 in 2024.

The PRIP scheme aims to build on this momentum with support from initiatives like CSIR’s INTENT for clinical trials, ICMR’s MedTech Mitra and Patent Mitra, and funding programs like DST’s Quantum Computing Mission and MeitY’s TIDE 2.0 and SAMRIDH. Leaders from DST, MeitY, DHR, and CSIR stressed the importance of digital health, AI, data-driven technologies, and industry-academia collaboration in driving innovation and commercialisation of research.

The workshop hosted over 100 participants from top scientific institutions, including NIPERs, IITs, CSIR labs, and government bodies, with discussions on emerging pharmaceutical and MedTech trends and strategies to transform research into market-ready products. Participants were invited to submit suggestions via the Expression of Interest (EoI) form on the Department of Pharmaceuticals’ website, open until April 7, 2025.

(PIB)

The Department of Pharmaceuticals, under the Ministry of Chemicals and Fertilisers, Government of India, held a workshop on the Promotion of Research and Innovation in the Pharma-MedTech Sector (PRIP) Scheme on March 12, 2025. Senior officials from key government departments participated, including Shri Amit Agrawal, Secretary, Department of Pharmaceuticals; Prof. Abhay Karandikar, Secretary, Department of Science and Technology (DST); Shri S. Krishnan, Secretary, Ministry of Electronics and Information Technology (MeitY); Dr. N. Kalaiselvi, Secretary, Department of Scientific and Industrial Research (DSIR) and Director General of CSIR; and Dr. Rajiv Bahl, Secretary, Department of Health Research (DHR) and DG, ICMR.The workshop focused on strengthening India’s innovation ecosystem in pharmaceuticals and medical technology. Shri Amit Agrawal highlighted the sector's rapid growth, noting the rising global share of advanced technologies like antibody-drug conjugates and gene therapy — projected to reach 20% of the top-100 drugs by value by 2030. He also pointed to the remarkable tenfold increase in Indian healthcare and life sciences startups, from 900 in 2020 to over 10,000 in 2024.The PRIP scheme aims to build on this momentum with support from initiatives like CSIR’s INTENT for clinical trials, ICMR’s MedTech Mitra and Patent Mitra, and funding programs like DST’s Quantum Computing Mission and MeitY’s TIDE 2.0 and SAMRIDH. Leaders from DST, MeitY, DHR, and CSIR stressed the importance of digital health, AI, data-driven technologies, and industry-academia collaboration in driving innovation and commercialisation of research.The workshop hosted over 100 participants from top scientific institutions, including NIPERs, IITs, CSIR labs, and government bodies, with discussions on emerging pharmaceutical and MedTech trends and strategies to transform research into market-ready products. Participants were invited to submit suggestions via the Expression of Interest (EoI) form on the Department of Pharmaceuticals’ website, open until April 7, 2025.(PIB)

Infrastructure Urban

06 Nov 2025

Concord Control Systems Limited Reports ~85% YoY Growth in H1 FY26

Concord Control Systems Limited (BSE: CNCRD | 543619), India’s leading manufacturer of embedded electronic systems and critical electronic solutions, announced its unaudited financial results for the half year ended September 30, 2025.Financial Highlights – H1 FY26 (YoY Comparison)Revenue from Operations rose to ₹815.45 million, up from ₹497.53 million in H1 FY25, marking a 63.90% year-on-year growth.EBITDA increased to ₹217.34 million, compared to ₹142 million in the same period last year.EBITDA Margin stood at 26.65%, compared to 28.54% in H1 FY25, with the decline attributed to ..

Infrastructure Urban

06 Nov 2025

Gateway Distriparks Announces Q2 FY25 Results

Gateway Distriparks Limited (GDL), one of India’s leading multimodal logistics providers, announced its financial results for the quarter ended 30 September 2025.For Q2, the company reported total revenue of INR 154.8 crore (H1: INR 316.9 crore), EBITDA of INR 20.56 crore (H1: INR 45.65 crore), PBT of INR –4.23 crore (H1: INR –0.28 crore), and PAT of INR –2.91 crore (H1: INR –0.37 crore). The company stated that these numbers reflect the consolidation of accounts following Snowman Logistics transitioning from an associate company to a subsidiary in December 2024.Commenting on the per..

Infrastructure Transport

06 Nov 2025

Last-Mile Connectivity a Prime Focus, Says Ms. Ashwini Bhide,

The IMC Chamber of Commerce and Industry (IMC) hosted a high-impact Managing Committee session today on the theme “Mumbai Metro: Transforming Connectivity and Commuting.” The session featured an insightful address by Ms. Ashwini Bhide, Managing Director, Mumbai Metro Rail Corporation Ltd. (MMRCL), who shared updates on key transport infrastructure developments across Mumbai and the MMR region.Emphasising the city’s critical economic role, Ms. Bhide noted, “Mumbai is the economic powerhouse of Maharashtra, with more than 95% of the region’s population living in urban areas. As Maharas..